Clinical Trial

Cognitive Screening in Lung Cancer Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.
Trial Details
NCT Number NCT06727370
Lead Sponsor European Institute of Oncology
Conditions Lung Disease, NSCLC (Non-small Cell Lung Cancer), SCLC
Enrollment 200 participants
Start Date 2024-01-10
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-10